ReviewFrontiers in cell and developmental biology2026

From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment.

Elisa Macrì et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.